PRCAT71 is a PCa-specific lncRNA. Credit score: Science Advances (2025). DOI: 10.1126/sciadv.adk6989
Northwestern Medication investigators have found {that a} novel lengthy noncoding RNA (lncRNA), that are normally 200 nucleotides longer than typical RNAs and are extensively expressed in cells, may function a prognostic biomarker and therapeutic goal for prostate most cancers, in accordance with a current research revealed in Science Advances.
Qi Cao, Ph.D., the Anthony J. Schaeffer, MD, Professor of Urology, and Rendong Yang, Ph.D., affiliate professor of Urology, had been co-corresponding authors of the research.
Prostate most cancers is the second-leading reason behind cancer-related dying amongst males within the U.S., with greater than 600,000 cancer-related deaths identified in 2024 alone, in accordance with a current report from the American Most cancers Society.
Rising research counsel that lengthy noncoding lncRNAs help prostate most cancers tumor progress and development. Nonetheless, the regulatory mechanisms of lncRNAs in prostate most cancers have remained unclear.
Utilizing superior RNA sequencing methods to research a number of prostate most cancers affected person tissues samples and cell strains, Cao’s crew found that lncRNA transcript 71 (PRCAT71) was extremely expressed completely in metastatic and first prostate most cancers tissue.
Moreover, the investigators discovered that concentrating on PRCAT71 lowered cancerous properties of prostate most cancers cells, particularly cell proliferation, colony formation and invasiveness.
In addition they found that PRCAT71 recruits the KHSRP protein to androgen receptor mRNA, stabilizing androgen receptor mRNA and growing androgen receptor signaling. This signaling is called a “master regulator” of prostate most cancers development.
The findings counsel that PRCAT71 could also be a possible diagnostic and prognostic biomarker and therapeutic goal for sufferers with prostate most cancers. Going ahead, the investigators intention to additional examine the non-canonical function of KHSRP in prostate most cancers and different cancers.
“Our study demonstrates a coordinated regulation of androgen receptor mRNA by lncRNA PRCAT71 and RNA binding protein KHSRP and provides insight that the PRCAT71-KHSRP-AR axis is a promising therapeutic target for treating prostate cancer,” the authors wrote.
Extra data:
Yongyong Yang et al, Androgen receptor–regulated lncRNA PRCAT71 promotes AR signaling via the interplay with KHSRP in prostate most cancers, Science Advances (2025). DOI: 10.1126/sciadv.adk6989
Supplied by
Northwestern College
Quotation:
Novel lengthy noncoding RNA could function therapeutic goal for prostate most cancers (2025, Might 23)
retrieved 24 Might 2025
from https://medicalxpress.com/information/2025-05-noncoding-rna-therapeutic-prostate-cancer.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
